Non-CFC Albuterol Transition Cost Increase Could Affect Patient Access, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Low-income patients will bear the burden of increased costs of transition from CFC albuterol to non-ozone depleting formulations, committee member says. GSK sampling and patient assistance programs are aimed at lessening burden. Longer transition period could allow introduction of competitors/generics, committee member suggests.